Pfizer Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2026-03-06 pm EST			5-day change	1st Jan Change
27.05 ^USD	+1.65%		-2.17%	+8.63%

Mar. 06	Top pharma companies racing to launch a weight-loss pill	RE
Mar. 06	Oil Shock Meets Job Shock

PFIZER INC : Gets a Neutral rating from Goldman Sachs

Published on 02/04/2026 at 08:05 am EST

MarketScreener with dpa-AFX Analyser

PFIZER INC.

+1.65%

Goldman Sachs confirms his opinion on the stock and remains Neutral. The target price continues to be set at USD 26.

Latest news about Pfizer Inc.

Mar. 06	Top pharma companies racing to launch a weight-loss pill	RE
Mar. 06	Oil Shock Meets Job Shock
Mar. 06	Pfizer Gains Chinese Approval for GLP-1 Weight Management Drug Enochlutide	MT
Mar. 06	China approves Pfizer GLP-1 drug for weight loss	RE
Mar. 05	Judge approves Pfizer, SEC settlement tied to insider trading at Cohen hedge fund	RE
Mar. 04	Johnson & Johnson launches website for direct-to-consumer sales	RE
Mar. 04	Bioxytran Inc Announces Positive Dose Optimization Results And Advances Toward Phase 3 Registrational Trial For ProLectin-M	CI
Mar. 04	Moderna rises on $2.25 billion settlement, clearing COVID vaccine patent dispute overhang	RE
Mar. 04	Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang	RE
Mar. 03	Moderna agrees to pay up to $2.25 billion to settle COVID vaccine patent dispute	RE
Mar. 03	From Calm to Caution
Mar. 03	Short war? Long war?
Mar. 02	US asks smaller drugmakers to discuss lowering prices for Medicaid	RE
Mar. 02	Pfizer Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 10:30 AM
Mar. 02	Pfizer CEO flags concerns with US FDA's vaccine leadership	RE

Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (24.5%); - other (1.9%). The United States accounts for 60.8% of net sales.

Employees

75,000

Sector

Pharmaceuticals

More about the company